Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis

Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis

Related Keywords

Taiwan ,Chengdu ,Sichuan ,China ,Hong Kong ,Italy ,Canada ,France ,Sweden ,United Kingdom ,Macau ,Chiesi Farmaceutici ,Thomas Eichholtz ,Haisco Pharmaceutical Group Co Ltd ,Head Of Global Research ,A Chiesi Group ,Chiesi Group ,B Corp ,Haisco Pharmaceutical ,Licensing Agreement ,Taiwan District ,Global Research ,Xiulian Fan ,General Manager ,Benefit Corporation ,